Form 4: Bionano Genomics COO Executes Tax Withholding Transaction

Bionano Genomics Chief Operating Officer Mark Oldakowski disposed of 27 shares to satisfy tax obligations related to RSU vesting.

Summary

• Mark Oldakowski, Chief Operating Officer of Bionano Genomics, Inc., reported a transaction involving the withholding of 27 shares of common stock.
• The transaction occurred on June 3, 2026, at a price of $1.30 per share.
• The disposal was executed to satisfy tax withholding obligations associated with the vesting of Restricted Stock Units (RSUs) granted on June 3, 2024.
• Following this transaction, the reporting person holds 868 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it is a routine administrative transaction required for tax compliance.

Positives

• The transaction is a routine administrative action related to tax obligations rather than a discretionary sale of shares.

Negatives

• The transaction reflects a minor reduction in the reporting person's direct equity stake.

Risks

• The company remains subject to market volatility and the inherent risks associated with the biotechnology sector.

Future Outlook

No forward-looking guidance or strategic outlook was provided in this filing.

Industry Context

StockSavvy.ai notes that tax-related share withholding is a standard corporate governance practice for executives receiving equity compensation and does not typically signal a change in management sentiment regarding company performance.

Comparison to Industry Standards

• The transaction follows standard SEC reporting requirements for executive compensation and tax compliance, consistent with practices at other publicly traded biotechnology firms.

Stakeholder Impact

• Minimal impact on shareholders as the transaction is a non-discretionary tax settlement.

Key Dates

Keywords

Bionano Genomics, BNGO, Insider Transaction, Form 4, Tax Withholding, Biotechnology